WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

This trial is testing a new immunotherapy drug called WTX212A — either on its own or combined with a PD-1/PD-L1 checkpoint inhibitor — in people with advanced non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) that has progressed after prior treatments, including at least 2 cycles of immunotherapy. **You may be eligible if...** - You are 18–75 years old - You have confirmed advanced NSCLC (stage IIB–IV) or extensive-stage SCLC - Your disease has progressed after at least one prior line of systemic therapy, and you have received PD-1/PD-L1 immunotherapy in your most recent treatment - Your general health is good (ECOG ≤ 1) - Expected survival of at least 3 months **You may NOT be eligible if...** - You have another serious uncontrolled medical condition (uncontrolled diabetes, active bleeding, severe heart disease) - You need repeated drainage of fluid from the chest or abdomen - You have had severe lung inflammation (pneumonitis, pulmonary fibrosis) related to prior treatment - You had to permanently stop immunotherapy (IO) due to a serious side effect - You have had another cancer within the past 3 years (with some exceptions) Talk to your doctor to see if this trial is right for you.